An Initiative by SAARTHI IAS
Maarg Manthan · Topic 11.27

India BioEconomy Report 2026: conceptual scope, scientific breakthroughs, strategic imperative, institutional initiatives, bottlenecks, way forward

Indian Economy › Agriculture: Crops, Inputs, Technology and Productivity · Topic 11.27

The India BioEconomy Report (IBER) 2026 is the tenth annual estimate of India's biotechnology-enabled economy, prepared by the Association of Biotechnology Led Enterprises (ABLE) for the Biotechnology Industry Research Assistance Council (BIRAC) and released by Dr Jitendra Singh on 19 March 2026. It values the BioEconomy at USD 195.3 billion in 2025, up 18 per cent from USD 165.7 billion in 2024, or 4.8 per cent of India's GDP. BioIndustrial is the largest of four segments at USD 90.2 billion, while BioAgri is USD 14.6 billion. The national target is USD 300 billion by 2030.

Share:
India BioEconomy Report 2026: conceptual scope, scientific breakthroughs, strategic imperative, institutional initiatives, bottlenecks, way forward - Indian Economy - MaargX UPSC Maarg Manthan

At a Glance

  • Released 19 March 2026 at BIRAC 14th Foundation Day; tenth edition
  • Size, 2025 USD 195.3 billion, up 18% from USD 165.7 billion
  • GDP share 4.8%, from 4.2 to 4.3% earlier
  • Segments, 2025 BioIndustrial 90.2, BioPharma 64.5, BioServices 26.0, BioAgri 14.6 (USD billion)
  • Targets USD 300 billion by 2030; USD 1 trillion by 2047
  • Exam link UPSC Prelims and Mains, Indian Economy: Agriculture: Crops, Inputs, Technology and Productivity

Where Does It Fit?

This Mains topic reads the aggregate economy behind the farm-level science in Biotechnology in the aid of agriculture: benefits and use and the crop debate in Genetically modified crops: way forward; High-value crops: economic, environmental, socio-cultural and policy factors. It links to seed and biotechnology basics in Seeds: Seed Replacement Rate (SRR), Breeder Seed, Foundation Seed, Certified Seed; Genetically Modified Crops; Biotechnology in Agriculture and to the sustainability theme of Second Green Revolution for sustainable livelihoods; Bringing Green Revolution to Eastern India (BGREI). Previous topic: Second Green Revolution for sustainable livelihoods; Bringing Green Revolution to Eastern India (BGREI). Next topic: e-nam-agmark-auction-sales/" class="maargx-auto-link" data-preview="At a Glance Regulated market Sale under a State APMC Act Authority Agricultural Produce Market Committee (APMC) Model law Model APMC Act…">Agriculture Market: Regulated Markets; APMC Acts of States; Model APMC Act 2003; e-NAM; AGMARK; Auction Sales.

What Does the India BioEconomy Report 2026 Measure?

Item Finding and meaning
Definition The report defines the BioEconomy as economic activity from the sustainable and circular use of renewable biological resources, including crops, forests, animals, fish and microorganisms, to produce food, feed, energy, materials and services
Segments Four: BioIndustrial (biofuels, fermentation products, bio-based chemicals, enzymes, biomaterials), BioPharma (biologics, biosimilars, vaccines, diagnostics, medical technologies), BioServices (contract research, clinical development, bioinformatics, digital biology, global capability centres) and BioAgri (crop protection biologicals, biofertilizers, biopesticides, biostimulants and biotechnology-enabled crops)
Value and growth USD 195.3 billion in 2025, an addition of USD 29.6 billion in a year; the 18 per cent growth is the highest in recent years. CAGR from 2020 to 2025 was 17.8 per cent, and the sector was about USD 10 billion in 2014
Segment shares BioIndustrial 46 per cent, BioPharma 33 per cent, BioServices 13 per cent and BioAgri 8 per cent, so manufacturing-led segments are nearly three-quarters of the total
Startups and money 11,855 biotech startups, with 1,780 added in 2025. Disclosed funding was USD 4.6 billion across over 200 deals in 2024 and 2025, including USD 1.58 billion in 100 deals in 2025, and 45 private equity exits worth over USD 6.15 billion
Regions Seven States crossed USD 10 billion and together hold about 78 per cent of the BioEconomy. South USD 93.2 billion, West 59.68, North 29.82 and East, including the North East, 12.58
Caveat on scope The report states that its classification is designed for its own analytical purposes and may not correspond directly to conventional industrial classification systems

Where Does Agriculture Sit Inside the BioEconomy?

BioAgri item Finding, 2025
Segment value USD 14.6 billion, up from USD 13.5 billion in 2024, an increase of USD 1.1 billion, about 8 per cent of the BioEconomy
GM crops (Bt cotton) USD 10.92 billion, up from USD 10.30 billion, nearly three-quarters of BioAgri
Crop protection and nutrition USD 3.65 billion, up from USD 3.20 billion. Biofertilizers rose from USD 1.44 billion to 1.61 billion, biopesticides from 0.96 to 1.10 and biostimulants from 0.80 to 0.94
Regional spread BioAgri follows crop patterns: West USD 7.98 billion, South 4.2, North 2.33 and East only 0.07 billion
Growth character The report calls BioAgri production-linked and crop-dependent, with incremental expansion and not structural change
2030 projection BioIndustrial USD 130 billion, BioPharma 100, BioServices 45 and BioAgri 25, which sum to USD 300 billion

What Else Should You Remember?

  • Fuel route: The ethanol blending programme links farm feedstock such as sugarcane, maize and surplus grain to industrial fermentation
  • BioE3 Policy: The Biotechnology for Economy, Environment and Employment (BioE3) Policy was announced in 2024. It names six sectors: bio-based chemicals, enzymes and biopolymers; smart proteins and functional foods; precision biotherapeutics; climate-resilient agriculture; carbon capture and utilisation; and marine and space biotechnology
  • Biofoundries: India’s first National Biofoundry Network was set up in August 2025 with six core institutions, within a network of 21 bio-enabler facilities
  • BioE3 response: The first round of DBT-BIRAC joint calls under BioE3 drew over 2,000 proposals, and about 40 per cent of the selected projects are led by startups and industry through public-private partnership
  • BioPharma SHAKTI: Announced in Union Budget 2026-27 with an outlay of Rs 10,000 crore over five years to build biologics and biosimilar capacity, global-grade regulation, more NIPER institutes and 1,000 accredited clinical trial sites
  • RDI Fund: A Rs 1 lakh crore Research, Development and Innovation Fund was launched on 3 November 2025, with BIRAC as a second-level fund manager for biotechnology
  • Regulation of gene-edited and GE plants: In 2025, the Department of Biotechnology notified Guidelines on Genetically Engineered Plants Containing Stacked Events, which set a biosafety assessment route for multi-trait plants. Gene-edited crops are named among future BioAgri drivers
  • BIRAC programmes: The Biotechnology Ignition Grant has nurtured over 1,000 innovations; SEED backed 153 startups with Rs 45 crore; BioNEST’s 94 incubators support more than 3,000 startups
  • Strategic imperative: Energy security through ethanol, health security through biologics and vaccines, farm sustainability through biological inputs, and jobs and exports through biomanufacturing and services. The report’s foreword sets a vision of a USD 1 trillion BioEconomy by 2047
  • Bottleneck: narrow agri base: Bt cotton is nearly three-quarters of BioAgri, and the segment grew by only USD 1.1 billion in 2025. Broad biological input use is rising but small
  • Bottleneck: regional concentration: Seven States hold about 78 per cent of value, and the East has USD 0.07 billion of BioAgri. Farmers in eastern and rainfed regions are left out of the gains, as seen in Second Green Revolution for sustainable livelihoods; Bringing Green Revolution to Eastern India (BGREI)
  • Bottleneck: pace needed: Reaching USD 300 billion by 2030 from USD 195.3 billion needs growth of about 9 per cent a year over five years, which the report says depends on sustained expansion across all segments and on the success of BioE3
  • Bottleneck: scale-up: The report’s own policy responses target scale-up barriers through biofoundries, biomanufacturing hubs, clinical trial sites and regulatory facilitation, which signals that moving from laboratory to industrial scale remains the main hurdle
  • Way forward: Broaden BioAgri beyond Bt cotton through biological inputs and approved gene-edited and stacked-trait crops, spread biofoundries and hubs beyond the seven leading States, link farm waste to bio-based products, keep regulation science-based and timely, and publish clear definitions so that year-on-year comparisons stay meaningful
  • Link to farm technology: Biological inputs fit with soil and nutrient management in Soil Health Card Scheme (Economy Lens) and fertiliser policy in Fertilisers: Urea Subsidy, Nutrient-Based Subsidy, Neem-Coated Urea, Fertigation; Natural Gas as Feedstock and Sulphur; Biofertilisers; Market Development Assistance Policy

Why Does It Matter for the Exam?

  1. Typical question: discuss the scope of India’s BioEconomy, the initiatives to promote it, and the bottlenecks and way forward
  2. Numbers to quote: USD 195.3 billion, 18 per cent growth, 4.8 per cent of GDP, USD 300 billion by 2030, 11,855 startups
  3. Policy to name: BioE3 Policy 2024, National Biofoundry Network, BioPharma SHAKTI, RDI Fund
  4. Agriculture angle: BioAgri USD 14.6 billion; Bt cotton USD 10.92 billion; biofertilizers, biopesticides, biostimulants
  5. Common errors: mixing the USD 195.3 billion total with the USD 90.2 billion BioIndustrial segment, or treating BioE3 as a pharma-only policy

As an analytical point, the report shows a BioEconomy led by fermentation, medicines and services, with agriculture a small and narrow part. The strategic task is to make biology work for farms as it has for ethanol and biologics, and to spread capacity beyond a few States.

Why Is This Topic Important?

  • Scope Four segments
  • Initiatives BioE3, biofoundries, funds
  • Bottlenecks Narrow agri base, concentration

What Came Next?

The next macro moves from production to markets, covering how agricultural produce is sold, stored and traded. Next topic: Agriculture Market: Regulated Markets; APMC Acts of States; Model APMC Act 2003; e-NAM; AGMARK; Auction Sales.

Key People and Terms

  • BioEconomy Economy from biological resources and biotech
  • BioAgri Agricultural biotechnology segment
  • Biofoundry Facility for engineering biology at scale
  • BioE3 Biotechnology for Economy, Environment and Employment
  • BIRAC Biotechnology Industry Research Assistance Council
  • ABLE Association of Biotechnology Led Enterprises

Exam Corner

Points to Remember

  • IBER 2026 released 19 March 2026; tenth edition.
  • BioEconomy USD 195.3 billion, 4.8 per cent of GDP.
  • Four segments: BioIndustrial, BioPharma, BioServices, BioAgri.
  • BioAgri: USD 14.6 billion, Bt cotton USD 10.92 billion.
  • Target: USD 300 billion by 2030.

Do Not Confuse With

  • BioEconomy and the bio-based industrial economy Total biotechnology-enabled value versus one segment, BioIndustrial
  • BioE3 Policy and BioPharma SHAKTI A broad 2024 biomanufacturing policy versus a Rs 10,000 crore biopharma programme in Budget 2026-27
  • BIRAC and ABLE The government’s biotech innovation council versus the industry association that prepares the report

Memory Hook

Measure it in four segments, power it with BioE3, widen it beyond Bt cotton.

Mains Angle

Examiners want the concept, evidence, institutions and a balanced view of gaps. Use the four segments as a frame and quote two or three numbers.

  • Scope Definition and four segments
  • Breakthroughs Ethanol, GLP-1, enzymes, biologics
  • Institutions BioE3, biofoundries, BIRAC, RDI Fund
  • Bottlenecks Narrow agri base, concentration, scale-up

A Question You May Face

An original practice question, not a past paper question.

“Discuss the conceptual scope of the BioEconomy as presented in the India BioEconomy Report 2026. What are the institutional initiatives, bottlenecks and way forward for India?”

How to Answer

  1. Intro Define the BioEconomy and quote USD 195.3 billion and 4.8 per cent of GDP.
  2. Body 1 Four segments, drivers and breakthroughs.
  3. Body 2 BioE3, biofoundries, BioPharma SHAKTI, RDI Fund.
  4. Body 3 Bottlenecks: narrow BioAgri, regional concentration, scale-up pace.
  5. Conclusion A USD 300 billion BioEconomy needs biology to work for farms, factories and clinics in every region.

GS Relevance

GS Paper 3: science and technology, awareness in biotechnology, Indian economy, inclusive growth and agriculture. A live 2026 report: questions ask what the BioEconomy means, why it matters strategically, which initiatives support it and what bottlenecks and way forward exist, including the role of agriculture.

Frequently Asked Questions

What is the India BioEconomy Report 2026?

The India BioEconomy Report 2026 is the tenth annual estimate of India's biotechnology-enabled economy, prepared by ABLE for BIRAC and released by Dr Jitendra Singh on 19 March 2026. It values the BioEconomy at USD 195.3 billion in 2025, up 18 per cent from the previous year.

What is India's BioEconomy worth in 2026?

According to the India BioEconomy Report 2026, India's BioEconomy was worth USD 195.3 billion in 2025, up from USD 165.7 billion in 2024, which is about 4.8 per cent of GDP. The national target is USD 300 billion by 2030, and the foreword speaks of USD 1 trillion by 2047.

What are the four segments of the BioEconomy?

The four segments are BioIndustrial at USD 90.2 billion, BioPharma at USD 64.5 billion, BioServices at USD 26.0 billion and BioAgri at USD 14.6 billion in 2025. Manufacturing-led BioIndustrial and BioPharma together make up nearly three-quarters of the total.

What is the BioE3 Policy?

The BioE3 Policy, Biotechnology for Economy, Environment and Employment, was announced in 2024 to speed up biomanufacturing. Its six sectors are bio-based chemicals, smart proteins, precision biotherapeutics, climate-resilient agriculture, carbon capture and utilisation, and marine and space biotechnology. It supports biofoundries and bio-AI hubs.

How big is agricultural biotechnology in India's BioEconomy?

BioAgri was USD 14.6 billion in 2025, about 8 per cent of the BioEconomy. GM crops, represented by Bt cotton, were USD 10.92 billion, and crop protection and nutrition, including biofertilizers, biopesticides and biostimulants, were USD 3.65 billion.

What are the bottlenecks for India's BioEconomy?

The report's data point to a narrow BioAgri base led by Bt cotton, concentration of about 78 per cent of value in seven States, and the need for roughly 9 per cent annual growth to reach USD 300 billion by 2030. Scale-up from laboratory to industry is the main hurdle that biofoundries aim to ease.

PYQ Practice — Statement Analysis

1 The India BioEconomy Report 2026 values India's BioEconomy at USD 195.3 billion for 2025.
True

This is up 18 per cent from USD 165.7 billion in 2024.

2 BioAgri is the largest segment of the BioEconomy.
False

BioIndustrial is the largest at USD 90.2 billion; BioAgri is USD 14.6 billion.

3 The BioE3 Policy was announced in 2024.
True

It stands for Biotechnology for Economy, Environment and Employment.

4 The India BioEconomy Report is prepared by ABLE for BIRAC.
True

The 2026 report is the tenth edition.

Share: